< 1 min reading time
There are rumours of potential changes to the FDA approval process particularly geared at devices processed through the 510(k) pathway. Will these changes affect reimbursement strategies?
If so, how?
Marked as spam
Meet your next client here. Join our medical devices group community.
Please log in to post questions.